IGF2BP2 and malignant colon neoplasm: In a cBioPortal curated set of non-redundant samples, the IGF2BP2 gene was altered in 18% of ovarian cancers, 14% of cervical cancers, 9% of lung cancers, 8% of uterine cancers, 5% of esophageal and gastric cancers, 4% of head and neck cancers, 3% of prostate cancers, 3% of bladder cancers, 2.8% of testicular cancers, 2.8% of skin cancers, 2.5% of breast cancers, 1.5% of colon cancers, 1.3% of soft tissue tumors, and 0.8% of pancreatic cancers (Figure 5A) [77,78,79].